Search research articles
Contact Us
Filters
Showing results (31-40 of 102) with videos related to
Page
of 11
Sort By:
BJU International
|
December 2, 2021
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?
Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
Urology
|
June 29, 2021
What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs
Mary E Westerman, Kelly K Bree, Andrea Kokorovic, et al.
BJU International
|
November 30, 2021
Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre
Niyati Lobo, Kelly K Bree, Patrick J Hensley, et al.
World Journal of Urology
|
June 12, 2021
Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center
Kelly K Bree, Patrick J Hensley, Nathan Brooks, et al.
Cancers
|
June 10, 2023
Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study
Xin Shelley Wang, Kelly K Bree, Neema Navai, et al.
The Journal of Urology
|
April 19, 2021
Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy
Kelly K Bree, Patrick J Hensley, Mary E Westerman, et al.
European Urology Oncology
|
December 18, 2021
Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin
Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
European Urology
|
October 11, 2018
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
Roger Li, William B Tabayoyong, Charles C Guo, et al.
Annals of Surgical Oncology
|
July 9, 2016
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
Neema Navai, William F Benedict, Guangcheng Zhang, et al.
European Urology
|
June 15, 2024
Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
Amanda A Myers, Wei Shen Tan, Valentina Grajales, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 102) with videos related to
Sort By:
Page
of 11
BJU International
|
December 2, 2021
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?
Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
Urology
|
June 29, 2021
What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs
Mary E Westerman, Kelly K Bree, Andrea Kokorovic, et al.
BJU International
|
November 30, 2021
Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre
Niyati Lobo, Kelly K Bree, Patrick J Hensley, et al.
World Journal of Urology
|
June 12, 2021
Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center
Kelly K Bree, Patrick J Hensley, Nathan Brooks, et al.
Cancers
|
June 10, 2023
Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study
Xin Shelley Wang, Kelly K Bree, Neema Navai, et al.
The Journal of Urology
|
April 19, 2021
Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy
Kelly K Bree, Patrick J Hensley, Mary E Westerman, et al.
European Urology Oncology
|
December 18, 2021
Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin
Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
European Urology
|
October 11, 2018
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
Roger Li, William B Tabayoyong, Charles C Guo, et al.
Annals of Surgical Oncology
|
July 9, 2016
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
Neema Navai, William F Benedict, Guangcheng Zhang, et al.
European Urology
|
June 15, 2024
Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
Amanda A Myers, Wei Shen Tan, Valentina Grajales, et al.
Page
of 11